IOL Chemicals and Pharmaceuticals Q1 Results FY27 : Uniresearch Prediction, Analyst Views and Watchpoints

IOL Chemicals and Pharmaceuticals Q1 Results FY27: Uniresearch projects Q1 FY27 Revenue at Rs 607 Cr (+10.0% YoY) and PAT at Rs 39 Cr (+13.3% YoY), based on the Uniresearch estimate. Q4 FY26 consolidated Revenue stood at Rs 619 Cr and PAT at Rs 53 Cr per consolidated quarterly financial data. Prepared by Kunal Singla, Associate Director.

Click Here – Get Free Investment Predictions

IOL Chemicals and Pharmaceuticals Q1 Results FY27: Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change
Revenue (Rs Cr)	552	607	+10.0%
PAT (Rs Cr)	34	39	+13.3%

Source: Q1 FY26 actuals from consolidated quarterly financial data. IOL Chemicals and Pharmaceuticals Q1 Results FY27 prediction applies Uniresearch trailing growth rates (Revenue +10.0%, PAT +13.3%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Track IOL Chemicals and Pharmaceuticals Live on Univest

Q4 FY26 Performance: Base for the Prediction

The IOL Chemicals and Pharmaceuticals Q1 Results FY27 prediction is anchored on Q4 FY26 consolidated Revenue of Rs 619 Cr and PAT of Rs 53 Cr per consolidated quarterly financial data. These Q4 FY26 actuals, combined with Uniresearch trailing growth estimates, form the basis of the Q1 Results FY27 Uniresearch projection.

The sequential comparison also provides useful context for interpreting the Q1 Results FY27 numbers. Q4 FY26 Revenue of Rs 619 Cr reflects year-end procurement and execution cycles that may not repeat equally in the Q1 FY27. For this reason, the more meaningful benchmark for investors is the year-on-year comparison: Q1 FY27 against Q1 FY26 actual Revenue of Rs 552 Cr, where the Uniresearch estimate targets +10.0% growth. Both the YoY and sequential reads should be monitored when the actual Q1 Results FY27 numbers are declared.

Uniresearch Estimate Behind the IOL Chemicals and Pharmaceuticals Q1 Results FY27 Projection

The IOL Chemicals and Pharmaceuticals Q1 Results FY27 prediction is derived from Uniresearch trailing analysis, which estimates FY27 Revenue growth of +10.0% and PAT growth of +13.3% year-on-year. Uniresearch applies these consensus growth rates to Q1 FY26 actuals to arrive at the Q1 FY27 projection of Rs 607 Cr Revenue and Rs 39 Cr PAT.

The Q1 FY27 estimation methodology for IOL Chemicals and Pharmaceuticals is worth clarifying for investors. Uniresearch applies full-year FY27 Uniresearch estimate growth rates (+10.0% Revenue, +13.3% PAT) to Q1 FY26 verified actuals to derive the Q1 FY27 projection of Rs 607 Cr Revenue and PAT Rs 39 Cr. This approach assumes the quarterly trajectory broadly mirrors the full-year consensus direction. Intra-year seasonality and one-time events can cause actual quarterly performance to diverge from this projection. Treat this Q1 FY27 Uniresearch estimate for IOL Chemicals and Pharmaceuticals as a directional benchmark, not a point forecast.

Get Expert Stock Picks on Univest

Key Watchpoints for the IOL Chemicals and Pharmaceuticals Q1 Results FY27

Revenue vs Consensus Target

Whether Q1 Results FY27 Revenue delivers in line with the Rs 607 Cr Uniresearch estimate (+10.0% YoY). Q4 FY26 Revenue was Rs 619 Cr.

PAT Margin Sustainability

PAT of Rs 39 Cr (+13.3% YoY) is the Q1 Results FY27 Uniresearch estimate. Q4 FY26 PAT was Rs 53 Cr. Margin stability signals operating leverage.

Management Commentary and Full-Year FY27 Guidance

Beyond the Q1 FY27 headline numbers, IOL Chemicals and Pharmaceuticals’s management commentary at the results announcement will be watched for full-year FY27 guidance on revenue trajectory, margin direction, and capital allocation. A confident outlook from management following an in-line or beat result could support re-rating, while cautious guidance despite solid numbers may limit near-term upside. Track post-result commentary on the Univest Screener for a complete picture.

Risks to the IOL Chemicals and Pharmaceuticals Q1 Results FY27 Prediction

Below-Consensus Revenue Growth

If actual Q1 Results FY27 Revenue underperforms the +10.0% growth target, the Rs 607 Cr prediction would be revised downward.

PAT Pressure from Costs or Provisions

One-time charges or higher costs could push PAT below Rs 39 Cr.

External and Macro Environment

The IOL Chemicals and Pharmaceuticals Q1 Results FY27 performance is also exposed to macro-level risks beyond IOL Chemicals and Pharmaceuticals’s direct control. Global commodity price movements, rupee-dollar exchange rate swings, domestic interest rate changes, and shifts in FII and DII sentiment toward the sector can affect input costs, realisations, and investor appetite simultaneously. A deteriorating macro environment in the Q1 FY27 could create downside risk to the Uniresearch Q1 FY27 projection even if company-specific execution remains on track.

IOL Chemicals and Pharmaceuticals Q1 Results FY27: Conclusion

The IOL Chemicals and Pharmaceuticals Q1 FY27 Uniresearch projection of Revenue Rs 607 Cr and PAT Rs 39 Cr is derived from Uniresearch trailing analysis. Track IOL Chemicals and Pharmaceuticals live on the Univest Screener for real-time updates.

Use the Univest Screener to Track IOL Chemicals and Pharmaceuticals Live

Download the Univest iOS App or Univest Android App for live IOL Chemicals and Pharmaceuticals Q1 FY27 result alerts.

Frequently Asked Questions on IOL Chemicals and Pharmaceuticals Q1 Results FY27

What is the Uniresearch prediction for IOL Chemicals and Pharmaceuticals Q1 Results FY27?

Ans. Uniresearch projects IOL Chemicals and Pharmaceuticals Q1 Results FY27 Revenue at Rs 607 Cr (+10.0% YoY) and PAT at Rs 39 Cr (+13.3% YoY), based on the Uniresearch estimate. Q1 FY26 actuals were Revenue Rs 552 Cr and PAT Rs 34 Cr.

What Uniresearch estimate is used for the IOL Chemicals and Pharmaceuticals Q1 Results FY27 prediction?

Ans. The IOL Chemicals and Pharmaceuticals Q1 Results FY27 prediction uses Uniresearch trailing analysis, projecting FY27 Revenue growth of +10.0% and PAT growth of +13.3% YoY. Average 12-month price target: Rs 693.

What were Q4 FY26 actuals behind the IOL Chemicals and Pharmaceuticals Q1 Results FY27 projection?

Ans. Q4 FY26 consolidated Revenue was Rs 619 Cr and PAT was Rs 53 Cr per consolidated quarterly financial data.

How reliable is the IOL Chemicals and Pharmaceuticals Q1 Results FY27 Uniresearch prediction?

Ans. The estimate is consensus-based, not a guaranteed outcome. Actual results may differ due to macro conditions and sector dynamics.

What base data is used for the IOL Chemicals and Pharmaceuticals Q1 Results FY27 Uniresearch projection?

Ans. The Uniresearch projection for Q1 Results FY27 uses Q1 FY26 consolidated actuals (Revenue Rs 552 Cr, PAT Rs 34 Cr) as the base, sourced from Screener.in quarterly financial data. Trailing YoY growth rates (Revenue +10.0%, PAT +13.3%) are applied to these actuals to derive the Q1 Results FY27 estimate. Actuals and projections can be tracked on the Univest Screener.

What are the key risks to the IOL Chemicals and Pharmaceuticals Q1 Results FY27 estimate?

Ans. Key risks: below-consensus revenue growth, margin compression, one-time provisions reducing PAT below Rs 39 Cr.

When will IOL Chemicals and Pharmaceuticals declare the actual IOL Chemicals and Pharmaceuticals Q1 Results FY27 data?

Ans. IOL Chemicals and Pharmaceuticals will declare Q1 FY27 results after the quarter ends. Track live updates on the Univest Screener.